Lexaria Bioscience Corp. (NASDAQ: LEXX) announced today that the Material Transfer Agreement (MTA) originally entered into on August 30, 2024 with an undisclosed pharmaceutical company (referred to as PharmaCO) has been extended through December 31, 2026. The agreement allows PharmaCO to evaluate Lexaria's DehydraTECH™ technology in a pre-clinical setting. The extension accommodates the time needed for PharmaCO to receive and review Lexaria's 2026 research and development (R&D) results related to GLP-1 drugs.
Under the extended MTA, the temporary exclusive license remains active and in force. The two parties will continue their relationship and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams. This suggests that positive outcomes from Lexaria's ongoing studies could lead to deeper collaboration or licensing agreements.
Over the past 12 months, Lexaria has advanced its GLP-1 development program. The company recently announced progress in three key 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to facilitate additional collaboration and potential licensing of Lexaria's technology.
Each of these studies is fully funded with existing corporate resources and is currently in process. Results are expected during the third and fourth quarters of the 2026 calendar year. The outcomes could significantly impact the pharmaceutical industry by demonstrating DehydraTECH's ability to improve oral delivery of GLP-1 drugs, which are widely used for diabetes and weight management. Improved bio-absorption and reduced side effects could enhance patient compliance and treatment efficacy.
Lexaria's DehydraTECH platform is a patented drug delivery formulation and processing technology that improves the way drugs enter the bloodstream through oral delivery. It has repeatedly shown the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.
For more information about Lexaria and its technology, visit www.lexariabioscience.com.
The extension of this MTA indicates sustained interest from the pharmaceutical industry in Lexaria's drug delivery technology. If the upcoming study results are favorable, it could lead to significant licensing deals or partnerships, potentially accelerating the development of more effective oral GLP-1 therapies. This matters for patients who may benefit from improved drug formulations and for investors tracking innovations in drug delivery systems.
